PT - JOURNAL ARTICLE AU - Kristen K. Ford AU - Michele Matchett AU - James E. Krause AU - Weifeng Yu TI - The P2X<sub>3</sub> Antagonist P<sup>1</sup>, P<sup>5</sup>-Di[inosine-5′] Pentaphosphate Binds to the Desensitized State of the Receptor in Rat Dorsal Root Ganglion Neurons AID - 10.1124/jpet.105.088070 DP - 2005 Oct 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 405--413 VI - 315 IP - 1 4099 - http://jpet.aspetjournals.org/content/315/1/405.short 4100 - http://jpet.aspetjournals.org/content/315/1/405.full SO - J Pharmacol Exp Ther2005 Oct 01; 315 AB - P2X3 purinergic receptors are predominantly expressed in dorsal root ganglion (DRG) neurons and play an important role in pain sensation. P2X3-specific antagonists are currently being sought to ameliorate pain in several indications. Understanding how antagonists interact with the P2X3 receptor can aid in the discovery and development of P2X3-specific antagonists. We studied the activity of the noncompetitive antagonist P1, P5-di[inosine-5′] pentaphosphate (IP5I) at the P2X3 receptor, compared with the well studied competitive antagonist TNP-ATP, using a whole-cell voltage-clamp technique in dissociated rat DRG neurons. IP5I blocked αβ-methylene ATP (αβ-meATP)-evoked P2X3 responses in a concentration-dependent manner (IC50 = 0.6 ± 0.1 μM). IP5I effectively inhibited P2X3 currents when pre-exposed to desensitized but not unbound receptors. Furthermore, IP5I equally blocked 1 and 10 μM αβ-meATP-evoked currents and had no effect on the desensitization rate constant of these currents. This supports the action of IP5I as a noncompetitive antagonist that interacts with the desensitized state of the P2X3 receptor. In contrast, TNP-ATP inhibited the current evoked by 1 μM αβ-meATP significantly more than the one evoked by 10 μM αβ-meATP. It also significantly slowed down the desensitization rate constant of the current. These results suggest that TNP-ATP acts as a competitive antagonist and competes with αβ-meATP at the P2X3 agonist binding site. These findings may help to explain why IP5I acts selectively at the fast-desensitizing P2X1 and P2X3 subtypes of the P2X purinoceptor, while having much less potency at slow-desensitizing P2X2 and P2X2/3 subtypes that lack the fast desensitized conformational state. The American Society for Pharmacology and Experimental Therapeutics